NEW YORK (GenomeWeb News) – Illumina today announced it has been selected as a preferred service provider for Cancer Research UK.
As a result, Illumina will provide a range of services, starting with whole genome sequencing, to support the International Cancer Genome Consortium, which aims to develop a comprehensive description of genomic, transcriptomic, and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.
Illumina and Cancer Research UK will initially focus their efforts on esophageal and prostate cancers, and potentially up to 1,500 whole human genome samples could be sequenced over a three-year period as part of the project. Illumina's HiSeq 2000 platform will be used to perform the whole genome sequencing.
As part of the collaboration, Illumina will also provide expression and epigenetic services for detailed characterization of transcriptomic and epigenomic changes in the target tumor types.
Additional terms of the deal were not released.